# Symbion A/S Symbion A/S is an Endowment / Foundation based in Copenhagen, Denmark. ## Overview - **Organization type:** Endowment / Foundation - **Headquarters:** Copenhagen, Denmark - **Region:** Europe - **Address:** Fruebjergvej 3, 2100 Copenhagen Ø, Denmark - **Founded:** 1984 - **Assets under management:** Undisclosed - **Website:** symbion.dk - **LinkedIn:** https://dk.linkedin.com/company/symbiondk ## Regulatory record - **Reports private funds:** No ## About Founded in 1984, Symbion A/S is a foundation anchored in Denmark's university ecosystem — its two largest shareholders are the University of Copenhagen and Copenhagen Business School. The foundation predates Copenhagen's ascendancy as a Nordic tech hub and was structured specifically to commercialize academic research, a mandate that still defines its site-selection logic: each of its five physical campuses sits adjacent to a major research institution or knowledge cluster. Chairman Jørgen Bardenfleth and CEO Peter Torstensen oversee an organization that functions less as a landlord and more as a community-attachment mechanism for the Greater Copenhagen innovation economy. Symbion's deployment model is platform-based rather than fund-based: it provides physical infrastructure, acceleration programming, and curated network access to its portfolio of resident companies. The five campuses — Symbion Østerbro, COBIS (Copenhagen Bio Science Park), Univate, Symbion Vesterbro, and Creators Floor at Frederiksberg — collectively span life sciences, deep tech, digital health, and enterprise software. COBIS anchors the life-science concentration, integrated with the Medicon Valley Alliance cluster that stretches across Greater Copenhagen and southern Sweden. Univate, co-located with the University of Copenhagen's innovation district, channels early-stage research spinouts. In 2024, the BioInnovation Institute merged its company-creation activities with Symbion's Accelerace program, consolidating the foundation's role as an operational partner to ventures that require lab infrastructure, regulatory guidance, and clinical-trial connections. Team size and total deployment metrics are not publicly disclosed — Symbion does not raise external funds or report a traditional AUM figure. Its value prop to the Copenhagen ecosystem is structural rather than transactional: the foundation retains long-term equity in select resident companies through its Accelerace vehicle but does not operate as a venture capital firm. The five campuses function as permanent infrastructure rather than milestone-dependent accelerators, meaning portfolio companies can remain on-site for years. Symbion Fonden, the affiliated philanthropic entity, provides a governance layer that separates the foundation's community mission from its commercial lease-and-equity operations. In May 2024, the BioInnovation Institute merger went live, folding BII's company-creation pipeline into Symbion's existing campus infrastructure (per the firm's official communications, 2024). Symbion's structural differentiator is its embedded-university architecture: rather than licensing IP and stepping away, the foundation co-locates with the research laboratories that generate its pipeline. University of Copenhagen and Copenhagen Business School are not merely partners — they are shareholders, which aligns the foundation's incentives with long-term research commercialization rather than short-cycle venture returns. No other Nordic startup platform combines permanent physical campuses, university equity stakes, and an in-house accelerator under a single foundation charter. ## Sectors - Life Sciences - Enterprise Software - Digital Health - Deep Tech ## Offices - Tagensvej 22, 2200 Copenhagen N, Denmark - Njalsgade 76, 2300 Copenhagen S, Denmark - Gammel Kongevej 11-13, 1610 Copenhagen V, Denmark - Nordre Fasanvej 215, 2000 Frederiksberg, Denmark ## People - Peter Torstensen — CEO - Jørgen Bardenfleth — Chairman of the Board ## Questions ### Who runs investment decisions at Symbion? CEO Peter Torstensen leads the organization, with Chairman Jørgen Bardenfleth overseeing the board. Symbion does not have a traditional investment committee making fund-allocation decisions — it operates a platform model that delivers physical infrastructure and acceleration services rather than deploying committed LP capital. The Accelerace program makes selective equity investments in resident startups, with decisions managed by Torstensen's team and board-approved strategic direction. ### How is Symbion related to the University of Copenhagen and Copenhagen Business School? Both universities are major shareholders in Symbion A/S, which makes the foundation structurally distinct from independent accelerators or coworking operators. The University of Copenhagen co-locates its innovation activities at the Univate campus on Njalsgade, while Copenhagen Business School anchors the Creators Floor campus in Frederiksberg. This equity relationship aligns Symbion's commercial incentives with the universities' research-commercialization timelines. ### Is Symbion a venture capital firm? No. Symbion is a foundation that provides physical campus infrastructure, community, and acceleration programming. It does not raise LP funds, charge management fees, or report an AUM. The Accelerace program can take equity positions in resident companies, but the foundation's primary revenue model is lease-based, supplemented by equity outcomes from the accelerator portfolio. ### What does the BioInnovation Institute merger mean for Symbion? In 2024, the BioInnovation Institute merged its company-creation activities with Symbion's existing Accelerace program. This consolidates Copenhagen's most significant life-science startup pipeline under Symbion's operational umbrella, giving BII-founded ventures direct access to COBIS campus infrastructure and the broader Symbion network of resident companies. ### What is the relationship between Symbion and Medicon Valley Alliance? Symbion is a key member of Medicon Valley Alliance, the life-science cluster organization that connects research institutions and companies across Greater Copenhagen and southern Sweden. COBIS, Symbion's bio-science campus, benefits from proximity to the cluster's clinical-trial infrastructure and pharmaceutical-company presence, which resident life-science startups leverage for partnerships and validation. ### What is Symbion Fonden and how is it separated from commercial operations? Symbion Fonden is the affiliated philanthropic foundation that provides a governance layer between the organization's community-development mission and its commercial lease-and-equity activities. This separation ensures that Symbion's long-term mandate — supporting Copenhagen's innovation ecosystem — remains intact regardless of individual campus or accelerator outcomes. ## Related profiles - [Symbion Power](https://altss.com/profile/symbion) - [Symetry Personal Retirement Fund](https://altss.com/profile/symetry-personal-retirement-fund) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/symbion-a-s Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology